These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 28439951)

  • 1. Incidence and risk factors of hypotension after intravenous fosphenytoin administration.
    Kim HK; Hwang IG; Koh IS; Kim DW
    J Clin Pharm Ther; 2017 Oct; 42(5):561-566. PubMed ID: 28439951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood pressure changes after intravenous fosphenytoin and levetiracetam in patients with acute cerebral symptoms.
    Kassab MY; Lobeck IN; Majid A; Xie Y; Farooq MU
    Epilepsy Res; 2009 Dec; 87(2-3):268-71. PubMed ID: 19854616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Literature Review Revisiting Phenytoin-Induced Sinus Arrest.
    Parsai S; Hariri I; Taleb M; Yoon Y
    Am J Ther; 2016; 23(4):e1091-3. PubMed ID: 25549077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients.
    Boucher BA; Feler CA; Dean JC; Michie DD; Tipton BK; Smith KR; Kramer RE; Young B; Parks BR; Kugler AR
    Pharmacotherapy; 1996; 16(4):638-45. PubMed ID: 8840370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of intravenous phenytoin toxicity with demographic, clinical, and dosing parameters.
    Binder L; Trujillo J; Parker D; Cuetter A
    Am J Emerg Med; 1996 Jul; 14(4):398-401. PubMed ID: 8768165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized evaluation of adverse events and length-of-stay with routine emergency department use of phenytoin or fosphenytoin.
    Coplin WM; Rhoney DH; Rebuck JA; Clements EA; Cochran MS; O'Neil BJ
    Neurol Res; 2002 Dec; 24(8):842-8. PubMed ID: 12500711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience with fosphenytoin in adults: pharmacokinetics, safety, and efficacy.
    Knapp LE; Kugler AR
    J Child Neurol; 1998 Oct; 13 Suppl 1():S15-8; discussion S30-2. PubMed ID: 9796747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probable valproate sodium-associated hypotension.
    Ota KS
    Am J Geriatr Pharmacother; 2010 Jun; 8(3):281-4. PubMed ID: 20624617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, Tolerability, and Pharmacokinetics of Fosphenytoin Loading in Patients With Subarachnoid Hemorrhage.
    Kim DW; Kim TE; Ji M; Chun YI
    Clin Neuropharmacol; 2015; 38(6):248-51. PubMed ID: 26536021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A critical review of fosphenytoin sodium injection for the treatment of status epilepticus in adults and children.
    Clay JL; Fountain NB
    Expert Rev Neurother; 2022 Jan; 22(1):1-13. PubMed ID: 34726961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canine status epilepticus treated with fosphenytoin: A proof of principle study.
    Patterson EE; Leppik IE; Coles LD; Podell M; Vite CH; Bush W; Cloyd JC
    Epilepsia; 2015 Jun; 56(6):882-7. PubMed ID: 25953073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of phenytoin after intravenous administration of fosphenytoin sodium in pediatric patients, adult patients, and healthy volunteers.
    Tanaka J; Kasai H; Shimizu K; Shimasaki S; Kumagai Y
    Eur J Clin Pharmacol; 2013 Mar; 69(3):489-97. PubMed ID: 22918614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fosphenytoin may cause hemodynamically unstable bradydysrhythmias.
    Adams BD; Buckley NH; Kim JY; Tipps LB
    J Emerg Med; 2006 Jan; 30(1):75-9. PubMed ID: 16434340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypocalcemia-like electrocardiographic changes after administration of intravenous fosphenytoin.
    Keegan MT; Bondy LR; Blackshear JL; Lanier WL
    Mayo Clin Proc; 2002 Jun; 77(6):584-6. PubMed ID: 12059129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus.
    Ogutu BR; Newton CR; Muchohi SN; Otieno GO; Edwards G; Watkins WM; Kokwaro GO
    Br J Clin Pharmacol; 2003 Jul; 56(1):112-9. PubMed ID: 12848783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures.
    Fischer JH; Patel TV; Fischer PA
    Clin Pharmacokinet; 2003; 42(1):33-58. PubMed ID: 12489978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin.
    O'Brien TJ; Cascino GD; So EL; Hanna DR
    Neurology; 1998 Oct; 51(4):1034-9. PubMed ID: 9781525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of intramuscular fosphenytoin vs intravenous phenytoin loading in the ED.
    Aaronson PM; Belgado BS; Spillane JP; Kunisaki TA
    Am J Emerg Med; 2011 Nov; 29(9):983-8. PubMed ID: 20685063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inappropriate fosphenytoin use in the ED.
    Johnson J; Wrenn K
    Am J Emerg Med; 2001 Jul; 19(4):293-4. PubMed ID: 11447516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purple Glove Syndrome after Phenytoin or Fosphenytoin Administration: Review of Reported Cases and Recommendations for Prevention.
    Garbovsky LA; Drumheller BC; Perrone J
    J Med Toxicol; 2015 Dec; 11(4):445-59. PubMed ID: 26135797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.